Triiodothyronine accelerates and enhances the antipsychotic effect of risperidone in acute schizophrenia

Vesta Steibliene, Adomas Bunevicius, Arunas Savickas, Arthur J. Prange, Charles Nemeroff, Robertas Bunevicius

Research output: Contribution to journalArticle

Abstract

In acute psychotic schizophrenia patients we investigated if the combination of triiodothyronine (T3) plus risperidone was more effective when compared to risperidone monotherapy. Thirty-two in-patients meeting the DSM-IV-TR diagnostic criteria for schizophrenia and without thyroid disease received risperidone (flexibly adjusted dose for tolerability) and were randomized to additionally receive either T3 (25 μg daily; risperidone plus T3 group) or placebo (risperidone plus placebo group). Treatment lasted until meeting the response to treatment criteria defined as score of ≤3 on the Clinical Global Impression Severity and Improvement scales. Acute psychotic episode symptom severity was evaluated using the Brief Psychiatric Rating Scale (BPRS) at treatment initiation and at the final study assessment. Fourteen patients were randomized to receive risperidone plus T3 and eighteen to receive risperidone plus placebo. The time until treatment response was shorter in the risperidone plus T3 group relative to the risperidone plus placebo group (25.5 ± 4.4 days vs 32.2 ± 8.2 days, respectively; p = 0.001). Moreover, there was a greater reduction of BPRS-total score (p = 0.01) in the risperidone plus T3 group relative to the risperidone plus placebo group. Treatment with T3 was associated with shorter time to treatment response (β = -0.440, p = 0.022) and with greater improvement in BPRS score (β = 0.240, p = 0.053), independent of patients' gender, age, baseline BPRS score and mean risperidone dose. The study confirms that addition of T3 to risperidone was associated with accelerated and enhanced treatment response in acutely psychotic schizophrenic patients.

Original languageEnglish (US)
Pages (from-to)9-16
Number of pages8
JournalJournal of Psychiatric Research
Volume73
DOIs
StatePublished - Feb 1 2016

Fingerprint

Risperidone
Triiodothyronine
Antipsychotic Agents
Schizophrenia
Brief Psychiatric Rating Scale
Placebos
Therapeutics
Placebo
Thyroid Diseases
Rating Scales
Diagnostic and Statistical Manual of Mental Disorders

Keywords

  • Acute psychotic episode
  • Antipsychotic
  • Risperidone
  • Schizophrenia
  • Treatment response
  • Triiodothyronine

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Biological Psychiatry
  • Arts and Humanities (miscellaneous)

Cite this

Triiodothyronine accelerates and enhances the antipsychotic effect of risperidone in acute schizophrenia. / Steibliene, Vesta; Bunevicius, Adomas; Savickas, Arunas; Prange, Arthur J.; Nemeroff, Charles; Bunevicius, Robertas.

In: Journal of Psychiatric Research, Vol. 73, 01.02.2016, p. 9-16.

Research output: Contribution to journalArticle

Steibliene, Vesta ; Bunevicius, Adomas ; Savickas, Arunas ; Prange, Arthur J. ; Nemeroff, Charles ; Bunevicius, Robertas. / Triiodothyronine accelerates and enhances the antipsychotic effect of risperidone in acute schizophrenia. In: Journal of Psychiatric Research. 2016 ; Vol. 73. pp. 9-16.
@article{7cd58a5dfaac43d399b811bf5412fdd6,
title = "Triiodothyronine accelerates and enhances the antipsychotic effect of risperidone in acute schizophrenia",
abstract = "In acute psychotic schizophrenia patients we investigated if the combination of triiodothyronine (T3) plus risperidone was more effective when compared to risperidone monotherapy. Thirty-two in-patients meeting the DSM-IV-TR diagnostic criteria for schizophrenia and without thyroid disease received risperidone (flexibly adjusted dose for tolerability) and were randomized to additionally receive either T3 (25 μg daily; risperidone plus T3 group) or placebo (risperidone plus placebo group). Treatment lasted until meeting the response to treatment criteria defined as score of ≤3 on the Clinical Global Impression Severity and Improvement scales. Acute psychotic episode symptom severity was evaluated using the Brief Psychiatric Rating Scale (BPRS) at treatment initiation and at the final study assessment. Fourteen patients were randomized to receive risperidone plus T3 and eighteen to receive risperidone plus placebo. The time until treatment response was shorter in the risperidone plus T3 group relative to the risperidone plus placebo group (25.5 ± 4.4 days vs 32.2 ± 8.2 days, respectively; p = 0.001). Moreover, there was a greater reduction of BPRS-total score (p = 0.01) in the risperidone plus T3 group relative to the risperidone plus placebo group. Treatment with T3 was associated with shorter time to treatment response (β = -0.440, p = 0.022) and with greater improvement in BPRS score (β = 0.240, p = 0.053), independent of patients' gender, age, baseline BPRS score and mean risperidone dose. The study confirms that addition of T3 to risperidone was associated with accelerated and enhanced treatment response in acutely psychotic schizophrenic patients.",
keywords = "Acute psychotic episode, Antipsychotic, Risperidone, Schizophrenia, Treatment response, Triiodothyronine",
author = "Vesta Steibliene and Adomas Bunevicius and Arunas Savickas and Prange, {Arthur J.} and Charles Nemeroff and Robertas Bunevicius",
year = "2016",
month = "2",
day = "1",
doi = "10.1016/j.jpsychires.2015.11.007",
language = "English (US)",
volume = "73",
pages = "9--16",
journal = "Journal of Psychiatric Research",
issn = "0022-3956",
publisher = "Elsevier Limited",

}

TY - JOUR

T1 - Triiodothyronine accelerates and enhances the antipsychotic effect of risperidone in acute schizophrenia

AU - Steibliene, Vesta

AU - Bunevicius, Adomas

AU - Savickas, Arunas

AU - Prange, Arthur J.

AU - Nemeroff, Charles

AU - Bunevicius, Robertas

PY - 2016/2/1

Y1 - 2016/2/1

N2 - In acute psychotic schizophrenia patients we investigated if the combination of triiodothyronine (T3) plus risperidone was more effective when compared to risperidone monotherapy. Thirty-two in-patients meeting the DSM-IV-TR diagnostic criteria for schizophrenia and without thyroid disease received risperidone (flexibly adjusted dose for tolerability) and were randomized to additionally receive either T3 (25 μg daily; risperidone plus T3 group) or placebo (risperidone plus placebo group). Treatment lasted until meeting the response to treatment criteria defined as score of ≤3 on the Clinical Global Impression Severity and Improvement scales. Acute psychotic episode symptom severity was evaluated using the Brief Psychiatric Rating Scale (BPRS) at treatment initiation and at the final study assessment. Fourteen patients were randomized to receive risperidone plus T3 and eighteen to receive risperidone plus placebo. The time until treatment response was shorter in the risperidone plus T3 group relative to the risperidone plus placebo group (25.5 ± 4.4 days vs 32.2 ± 8.2 days, respectively; p = 0.001). Moreover, there was a greater reduction of BPRS-total score (p = 0.01) in the risperidone plus T3 group relative to the risperidone plus placebo group. Treatment with T3 was associated with shorter time to treatment response (β = -0.440, p = 0.022) and with greater improvement in BPRS score (β = 0.240, p = 0.053), independent of patients' gender, age, baseline BPRS score and mean risperidone dose. The study confirms that addition of T3 to risperidone was associated with accelerated and enhanced treatment response in acutely psychotic schizophrenic patients.

AB - In acute psychotic schizophrenia patients we investigated if the combination of triiodothyronine (T3) plus risperidone was more effective when compared to risperidone monotherapy. Thirty-two in-patients meeting the DSM-IV-TR diagnostic criteria for schizophrenia and without thyroid disease received risperidone (flexibly adjusted dose for tolerability) and were randomized to additionally receive either T3 (25 μg daily; risperidone plus T3 group) or placebo (risperidone plus placebo group). Treatment lasted until meeting the response to treatment criteria defined as score of ≤3 on the Clinical Global Impression Severity and Improvement scales. Acute psychotic episode symptom severity was evaluated using the Brief Psychiatric Rating Scale (BPRS) at treatment initiation and at the final study assessment. Fourteen patients were randomized to receive risperidone plus T3 and eighteen to receive risperidone plus placebo. The time until treatment response was shorter in the risperidone plus T3 group relative to the risperidone plus placebo group (25.5 ± 4.4 days vs 32.2 ± 8.2 days, respectively; p = 0.001). Moreover, there was a greater reduction of BPRS-total score (p = 0.01) in the risperidone plus T3 group relative to the risperidone plus placebo group. Treatment with T3 was associated with shorter time to treatment response (β = -0.440, p = 0.022) and with greater improvement in BPRS score (β = 0.240, p = 0.053), independent of patients' gender, age, baseline BPRS score and mean risperidone dose. The study confirms that addition of T3 to risperidone was associated with accelerated and enhanced treatment response in acutely psychotic schizophrenic patients.

KW - Acute psychotic episode

KW - Antipsychotic

KW - Risperidone

KW - Schizophrenia

KW - Treatment response

KW - Triiodothyronine

UR - http://www.scopus.com/inward/record.url?scp=84958962131&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84958962131&partnerID=8YFLogxK

U2 - 10.1016/j.jpsychires.2015.11.007

DO - 10.1016/j.jpsychires.2015.11.007

M3 - Article

C2 - 26679760

AN - SCOPUS:84958962131

VL - 73

SP - 9

EP - 16

JO - Journal of Psychiatric Research

JF - Journal of Psychiatric Research

SN - 0022-3956

ER -